Toronto

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• High blood pressure4 trials
• Alzheimer disease2 trials
• Amyloidosis2 trials
• Metastatic breast cancer2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Chronic kidney disease1 trial
• Obesity1 trial
• Prostate cancer1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 36 trials
• Phase 24 trials
• Phase 13 trials
• Phase 1/21 trial

Status

• Recruiting5 trials
• Completed4 trials
• Active, not recruiting3 trials
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Alnylam Pharmaceuticals10 trials
• Olema Pharmaceuticals, Inc.2 trials
• Arvinas Androgen Receptor, Inc.1 trial
• Syndax Pharmaceuticals1 trial

Running trials

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

  Contact: Syndax Pharmaceuticals

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Recruiting

  A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

  NCT07214727· Phase 1· Alnylam Pharmaceuticals· Source

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

  NCT06393712· Phase 2· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

  NCT05231785· Phase 1· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• Childhood cancers1 recruiting
• High blood pressure1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Terminated

  A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

  NCT05761301· Phase 1/2· Alnylam Pharmaceuticals· Source

• Completed

  Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

  NCT05177042· Phase 1· Arvinas Androgen Receptor, Inc.· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

  NCT04936035· Phase 2· Alnylam Pharmaceuticals· Source